Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. (Q52813540)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 December 2016

Language	Label	Description	Also known as
English	Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.	scientific article published on 13 December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. (English)

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

1 reference

based on heuristic

inferred from title

chronic idiopathic myelofibrosis

1 reference

based on heuristic

inferred from title

author name string

Thamer Sliwa

1

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Christine Beham-Schmid

2

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Sonja Burgstaller

3

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Veronika Buxhofer-Ausch

4

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Günther Gastl

5

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Klaus Geissler

6

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Maria Krauth

7

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Peter Krippl

8

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Alois Lang

9

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Andreas Petzer

10

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Stefan Wöhrer

11

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Albert Wölfler

12

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Heinz Gisslinger

13

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

publication date

13 December 2016

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Vienna Clinical Weekly

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

129

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

9-10

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

293-302

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

https://scigraph.springernature.com/pub.10.1007/s00508-016-1120-8

0 references

The role of cytokines in the initiation and progression of myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Somatic mutations of calreticulin in myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

MPNs as Inflammatory Diseases: The Evidence, Consequences, and Perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

A comprehensive review of pacritinib in myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

The role of interferon-alpha in the treatment of idiopathic myelofibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Disseminated tuberculosis associated with ruxolitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

1 reference

https://api.crossref.org/works/10.1007%2FS00508-016-1120-8

21 January 2018

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypercalcemia and adrenal insufficiency in a patient with myelofibrosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts

1 reference

https://pubmed.ncbi.nlm.nih.gov/27966016

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00508-016-1120-8

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

1 reference

Europe PubMed Central

8 May 2018

http://europepmc.org/abstract/MED/27966016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52813540&oldid=1590469649"